Full-Time

Head of Communications

Executive Director

Posted on 8/8/2024

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$260k - $301kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Lab & Research
Life Sciences
Required Skills
Communications
Social Media
Requirements
  • 12 years of Communications experience with 5 years minimum in a biotech/pharmaceutical company or at a PR/communications agency working with biotech/pharmaceutical clients.
  • Demonstrated experience crafting and executing successful traditional media, social media and internal communications strategies.
  • Experience working with high performing teams and demonstrated ability to collaborate, lead, facilitate, influence and organize across groups and at multiple levels of an organization.
  • Understanding of SEC and FDA regulations impacting communications.
  • Education: bachelor's degree required.
Responsibilities
  • Advance RevMed's corporate visibility and drive understanding of the company's strategy, programs, capabilities and people across priority audiences, internally and externally.
  • Advance capability for external affairs, including media relations, C-suite thought leadership and executive visibility, data/regulatory milestone communications, launch readiness activities, educational campaigns and other public relations engagement tactics/channels.
  • Serve as a company spokesperson with media; develop and build relationships with top-tier business/financial/industry trade press.
  • Oversee development of communications materials, across corporate, pipeline and product communications, including launch readiness materials; materials may include press releases, talking points/Q&A, social/digital content, etc, in collaboration with external agency partners, senior leadership and internal colleagues in Investor Relations, Commercial, Medical Affairs, Patient Advocacy, Legal, and other parts of the organization.
  • In partnership with Investor Relations, plan and prepare for business and scientific events and conferences working closely across various disciplines.
  • Oversee corporate governance (e.g., annual report) and quarterly financial communications, business development communications and CSR/ESG efforts.
  • Prepare company spokespeople for media interviews and other engagements, including training spokespeople, as needed, and ensuring company spokespeople are prepared to address key issues as they emerge.
  • Develop and oversee comprehensive, and compliant corporate branding strategy.
  • Build and execute well organized and consistent internal communications capabilities to support employee engagement, understanding, alignment and inclusion.
  • Collaborate with HR to ensure employee communications are well coordinated and aligned to broader internal and external objectives and messaging.
  • Demonstrate an unwavering commitment to patients, in alignment with patient advocacy function, and oversee efforts on patient-focused communication/engagement programs to drive employee engagement and promote the voice of the patient.
  • Oversee and provide counsel for issues/crisis communications.
  • Oversee social/digital and omnichannel strategy internally and externally.
  • Manage future direct reports and multiple agency partners.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

-2%

1 year growth

-3%

2 year growth

7%
Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in capital for R&D.
  • FDA fast-tracking supports their RAS-targeted therapy pipeline.
  • Growing interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • EQRx acquisition may pose integration challenges and cultural clashes.
  • $600M public stock offering could lead to shareholder dilution.
  • Focus on RAS-addicted cancers limits market scope and increases competition risk.

What makes Revolution Medicines unique

  • Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their unique synthesis technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

INACTIVE